Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.40 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | GBA1 | P04062 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | ASGR1 | P07306 | 1/20 | 0.33 |
| ▸ | FPR3 | P25089 | 1/20 | 0.33 |
| ▸ | FPR2 | P25090 | 1/20 | 0.33 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27498416 | 0.91 | CA14 (0.39) | CHRNB2CHRNB4CHRNA3CHRNA4CA14 | |
| SCHEMBL10260946 | 0.89 | HDAC6 (0.40) | CHRNB2CHRNA4CA14HDAC6HDAC1 | |
| SCHEMBL19865534 | 0.88 | CHRNB2 (0.37) | CHRNB2CHRNB4CHRNA3CHRNA4CA14 | |
| SCHEMBL1094425 | 0.88 | TDP1 (0.42) | CHRNB2CHRNB4CHRNA3CHRNA4CA14 | |
| SCHEMBL2478206 | 0.86 | TDP1 (0.44) | CHRNB2CHRNB4CHRNA3CHRNA4CA14 | |
| SCHEMBL22492482 | 0.86 | CA14 (0.37) | CHRNB2CHRNB4CHRNA3CHRNA4CA14 | |
| SCHEMBL1109797 | 0.84 | TDP1 (0.47) | CHRNB2CHRNB4CHRNA3CHRNA4CA14 | |
| SCHEMBL17267507 | 0.84 | TDP1 (0.47) | CHRNB2CHRNB4CHRNA3CHRNA4CA14 | |
| SCHEMBL12281742 | 0.84 | TDP1 (0.47) | CHRNB2CHRNB4CHRNA3CHRNA4CA14 | |
| SCHEMBL30011319 | 0.84 | TDP1 (0.47) | CHRNB2CHRNB4CHRNA3CHRNA4CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1340 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119875456-A | Preparation method of low-temperature-resistant coating for natural gas metal pipeline | 廊坊市泰锐通石油燃气管道工程有限公司 | 2025-04-25 | — | — | CN | claimed |
| US-11673868-B2 | Amino pyrimidine derivatives | NOVARTIS AG (CH) | 2023-06-13 | — | — | US | claimed |
| US-20220041561-A1 | Amino Pyrimidine Derivatives | NOVARTIS AG (CH) | 2022-02-10 | — | — | US | claimed |
| US-20260144795-A1 | SPIROMACROCYCLIC OREXIN 2 RECEPTOR AGONISTS | H. LUNDBECK A/S (DK) | 2026-05-28 | — | — | US | disclosed |
| EP-4747260-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| WO-2026107406-A1 | p53 HETEROBIFUNCTIONAL CONJUGATES AND USES THEREOF | Design Therapeutics, Inc. (US) | 2026-05-21 | — | — | WO | disclosed |
| EP-4743178-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER AND METABOLIC DISEASES | Katholieke Universiteit Leuven KU Leuven Research & Development (BE) | 2026-05-20 | — | — | EP | disclosed |
| EP-4743447-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER AND METABOLIC DISEASES | Katholieke Universiteit Leuven KU Leuven Research & Development (BE) | 2026-05-20 | — | — | EP | disclosed |
| EP-4743465-A1 | BICYCLIC MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2026-05-20 | — | — | EP | disclosed |
| WO-2026101971-A2 | EGFR INHIBITORS FOR TREATING DISEASE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| EP-4739390-A1 | 2-(1H-INDOL-4-YL)METHYL)2H-INDAZOLE DERIVATIVES AS FACTOR B INHIBITORS | Sitala Bio Ltd (GB) | 2026-05-13 | — | — | EP | disclosed |
| CN-1129000-A | New compound and its prepn. | FUJISAWA PHARMACEUTICAL CO (JP) | 1996-08-14 | — | — | CN | disclosed |
| US-5523302-A | ANTICOAGULANTS, CARDIOVASCULAR DISORDERS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-06-04 | — | — | US | disclosed |
| EP-0706532-A1 | NEW COMPOUND AND ITS PREPARATION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-04-17 | — | — | EP | disclosed |
| WO-1995000537-A1 | NEW COMPOUND AND ITS PREPARATION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-01-05 | — | — | WO | disclosed |
| EP-0301751-B1 | PYRIDINIUM DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1993-03-10 | — | — | EP | disclosed |
| US-4962113-A | PLATELET ACTIVATING FACTOR ANTAGONISTS | TAKEDA CHEMICAL INDUSTRIES, LTD (JP) | 1990-10-09 | — | — | US | disclosed |
| EP-0301751-A1 | Pyridinium derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1989-02-01 | — | — | EP | disclosed |
| US-4753933-A | ANXIOLYTIS, ANTIEPILEPTICS, MUSCLE RELAXANTS | RHONE-POULENC SANTE (FR) | 1988-06-28 | — | — | US | disclosed |
| US-4007184-A | BACTERICIDE, ANIMAL GROWTH REGULATOR | PFIZER INC. (US) | 1977-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144795-A1 | SPIROMACROCYCLIC OREXIN 2 RECEPTOR AGONISTS | HCRTR2, HCRTR1, CRHR1 | CHRNB2 94/4885CHRNB4 106/4885CHRNA3 69/4885 |
| US-20220041561-A1 | Amino Pyrimidine Derivatives | BTK, LCK, JAK1 | CHRNB2 3056/4885CHRNB4 2869/4885CHRNA3 3141/4885 |
| US-11673868-B2 | Amino pyrimidine derivatives | BTK, LCK, JAK1 | CHRNB2 2818/4885CHRNB4 2657/4885CHRNA3 2872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.